221 related articles for article (PubMed ID: 36865917)
1. Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology.
Deng G; Ren J; Li R; Li M; Jin X; Li J; Liu J; Gao Y; Zhang J; Wang X; Wang G
Front Pharmacol; 2023; 14():1125753. PubMed ID: 36865917
[No Abstract] [Full Text] [Related]
2. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
3. Analysis of long noncoding RNA-associated competing endogenous RNA network in glucagon-like peptide-1 receptor agonist-mediated protection in β cells.
Cui LJ; Bai T; Zhi LP; Liu ZH; Liu T; Xue H; Yang HH; Yang XH; Zhang M; Niu YR; Liu YF; Zhang Y
World J Diabetes; 2020 Sep; 11(9):374-390. PubMed ID: 32994866
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction.
Liu Z; Bian N; Wu S; Fan Y; Li H; Yu J; Guo J; Chen D
Front Cardiovasc Med; 2022; 9():1019120. PubMed ID: 36277800
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
6. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.
Xia L; Shen T; Dong W; Su F; Wang J; Wang Q; Niu S; Fang Y
Diabetes Res Clin Pract; 2021 Jul; 177():108904. PubMed ID: 34102249
[TBL] [Abstract][Full Text] [Related]
9. Identification of key candidate genes and pathways revealing the protective effect of liraglutide on diabetic cardiac muscle by integrated bioinformatics analysis.
Dong Y; Yan S; Li GY; Wang MN; Leng L; Li Q
Ann Transl Med; 2020 Mar; 8(5):181. PubMed ID: 32309328
[TBL] [Abstract][Full Text] [Related]
10. Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
He L; Yang N; Xu L; Ping F; Li W; Li Y; Zhang H
Diabetes Ther; 2020 Sep; 11(9):2121-2143. PubMed ID: 32734559
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of Carthami Flos and Lepidii Semen drug pair in inhibition of myocardial fibrosis by improving cardiac microenvironment based on network pharmacology and animal experiment].
Wang Y; Wang Z; Wang C; Ma DF
Zhongguo Zhong Yao Za Zhi; 2022 Feb; 47(3):753-763. PubMed ID: 35178959
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics and network pharmacology analysis of drug targets and mechanisms related to the comorbidity of epilepsy and migraine.
Shen Z; Pu S; Cao X; Tang M; Wang S; Bai D; Jiang G
Epilepsy Res; 2023 Jan; 189():107066. PubMed ID: 36571905
[TBL] [Abstract][Full Text] [Related]
14. Combined Network Pharmacology and Molecular Docking to Verify the Treatment of Type 2 Diabetes with
Mao J; Wang G; Yang L; Tan L; Tian C; Tang L; Fang L; Mu Z; Zhu Z; Li Y
Comput Math Methods Med; 2023; 2023():9150324. PubMed ID: 36820318
[TBL] [Abstract][Full Text] [Related]
15. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
[TBL] [Abstract][Full Text] [Related]
16. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
17. Exploration of Pharmacological Mechanisms of Dapagliflozin against Type 2 Diabetes Mellitus through PI3K-Akt Signaling Pathway based on Network Pharmacology Analysis and Deep Learning Technology.
Wu J; Chen Y; Shi S; Liu J; Zhang F; Li X; Liu X; Hu G; Dong Y
Curr Comput Aided Drug Des; 2024 Jan; ():. PubMed ID: 38204223
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
19. Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation.
Bao W; Sun H; Wu X; Xu J; Zhang H; Cao L; Fan Y
Dis Markers; 2022; 2022():1927688. PubMed ID: 36284987
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
